SeekingAlpha · Aug 11, 2026
Caris Life Sciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-11. The following slide deck was published by Caris Life Sciences, Inc.
CA
NASDAQ · CAI
Caris Life Sciences, Inc.
Healthcare · Biotechnology
$20.97
Down-$0.66 (-3.05%)
Updated Aug 19, 2026, 8:04 AM
SID Score
5.9/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.49B
- P/E ratio
- -34.61
- Dividend yield
- 0.00%
- 52-week range
- $14.19 – $29.32
- Volume
- 3.6M
- Avg. volume
- 1.42M
Price performance
CAI price history
1M range · 21 trading sessions · Daily adjusted prices
CAI closed at $20.97 after 21 trading sessions, up 33.31% for the selected period.
- Last close
- $20.97
- Period change
- +33.31%
- Period low
- $15.38
- Period high
- $23.40
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $21.31 | $21.64 | $20.78 | $20.97 | 3.6M |
| Aug 17, 2026 | $22.00 | $22.19 | $21.52 | $21.63 | 2.77M |
| Aug 14, 2026 | $22.26 | $22.43 | $21.445 | $21.80 | 3.87M |
| Aug 13, 2026 | $22.84 | $23.12 | $22.14 | $22.18 | 2.97M |
| Aug 12, 2026 | $22.90 | $22.965 | $21.99 | $22.26 | 4.02M |
| Aug 11, 2026 | $23.39 | $23.66 | $22.99 | $23.14 | 6.04M |
| Aug 10, 2026 | $22.68 | $23.44 | $22.68 | $23.40 | 5.91M |
| Aug 7, 2026 | $20.695 | $22.77 | $20.1201 | $22.74 | 9.4M |
| Aug 6, 2026 | $19.00 | $20.11 | $17.945 | $20.00 | 11.27M |
| Aug 5, 2026 | $16.03 | $16.54 | $15.9616 | $16.45 | 6.77M |
| Aug 4, 2026 | $16.26 | $16.55 | $15.91 | $16.10 | 4.84M |
| Aug 3, 2026 | $15.92 | $16.59 | $15.835 | $16.32 | 4.9M |
| Jul 31, 2026 | $16.05 | $16.14 | $15.23 | $15.67 | 3.51M |
| Jul 30, 2026 | $15.58 | $16.17 | $15.46 | $16.09 | 4.54M |
| Jul 29, 2026 | $15.43 | $16.00 | $15.26 | $15.59 | 5.62M |
| Jul 28, 2026 | $15.74 | $16.03 | $15.41 | $15.59 | 3.62M |
| Jul 27, 2026 | $15.69 | $16.02 | $15.46 | $15.63 | 3.45M |
| Jul 24, 2026 | $15.74 | $15.945 | $15.18 | $15.52 | 4.93M |
| Jul 23, 2026 | $15.20 | $16.205 | $15.11 | $15.65 | 2.54M |
| Jul 22, 2026 | $15.61 | $15.84 | $15.29 | $15.38 | 1.99M |
| Jul 21, 2026 | $15.50 | $16.055 | $15.13 | $15.73 | 3.19M |
Latest CAI news
The latest Smart Investors Daily articles mentioning CAI.
Stock researchCompany · Overview
CAI research
Overview
Company profile and research snapshot.
Company profile
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $35.00
- Implied upside
- —
- Analysts
- 12
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Evercore ISI Group | Outperform | — |
| Aug 6, 2026 | BTIG | Buy | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
| Jul 2, 2026 | BTIG | Buy | — |
| May 8, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
Caris Life Sciences: Guidance Raised, Valuation Still Attractive
Caris Life Sciences (CAI) Q2 beats with raised guidance, margin expansion and Caris Detect launch.
Benzinga · Aug 6, 2026
Evercore ISI Group Maintains Outperform on Caris Life Sciences, Raises Price Target to $26
Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and raises the price target from $25 to $26.
SeekingAlpha · Aug 5, 2026
Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call Transcript
Caris Life Sciences, Inc. (CAI) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsJ.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
